Real-World Use of GLP-1 Receptor Agonist Liraglutide in Adolescents with Obesity: A First Longitudinal Single-Center Analysis from Switzerland †
Cees Noordam, Urs Eiholzer, Claudia Katschnig, Aikaterini Stasinaki, Ilja Dubinski, Andrea E Scaramuzza, Sanja Musić Milanović, Eli Hershkovitz · 2025
Read Real-World Use of GLP-1 Receptor Agonist Liraglutide in Adolescents with Obesity: A First Longitudinal Single-Center Analysis from Switzerland † by Cees Noordam, Urs Eiholzer, Claudia Katschnig, Aikaterini Stasinaki, Ilja Dubinski, Andrea E Scaramuzza, Sanja Musić Milanović, Eli Hershkovitz (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12732185.txt.
Description
Cees Noordam and co-authors report the first long-term real-world look at a weight drug for teens in Switzerland in a 2025 study. The drug, liraglutide, mimics a gut hormone and proved effective in formal trials, but everyday results in young people were scarce. Adolescent obesity has few treatment options, so real-world evidence carries weight.
The team reviewed records of twenty-two adolescents treated at one Swiss children's hormone center. All also received standard lifestyle support. Tracking weight and safety over time shows how trial results hold up in clinic life, where adherence varies. The analysis gives doctors and families a realistic picture of benefits and burdens before starting a long course.
Catalog record
| CREATOR | Cees Noordam, Urs Eiholzer, Claudia Katschnig, Aikaterini Stasinaki, Ilja Dubinski, Andrea E Scaramuzza, Sanja Musić Milanović, Eli Hershkovitz |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 24 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |